Inventiva (IVEVF) Receivables - Accured (2022 - 2023)
Inventiva (IVEVF) posted Receivables - Accured of $86025.0 for Q2 2023, up 29.72% on a QoQ basis from $66316.1 in Q4 2022.
Powered by 
Analysis
Inventiva (IVEVF) Receivables - Accured (2022 - 2023) Analysis & Trends
Inventiva has reported Receivables - Accured for 2 years, with the latest figure at $86025.0 in Q2 2023.
- On a quarterly basis, Receivables - Accured changed N/A year-over-year to $86025.0 in Q2 2023; TTM through Jun 2023 was $86025.0, a N/A change from a year earlier, with the FY2022 full-year figure at $66316.1, changed N/A from the prior year.
- Receivables - Accured was $86025.0 for Q2 2023 at Inventiva, up from $66316.1 in the prior quarter.
- The five-year high for Receivables - Accured was $86025.0 in Q2 2023, with the low at $66316.1 in Q4 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables - Accured (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.04 Bn | 624.28 Bn | 17.26 Bn | - |
| 2 | AbbVie | 440.25 Bn | 433.68 Bn | 12.70 Bn | - |
| 3 | Merck | 365.65 Bn | 358.51 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 266.64 Bn | 258.95 Bn | 11.24 Bn | - |
| 5 | Pfizer | 159.03 Bn | 147.33 Bn | 10.94 Bn | - |
| 6 | Sanofi | 52.43 Bn | 45.05 Bn | 10.79 Bn | - |
| 7 | Revolution Medicines | 44.19 Bn | 44.19 Bn | - | - |
| 8 | Incyte | 25.29 Bn | 20.75 Bn | 1.57 Bn | - |
| 9 | United Therapeutics | 21.44 Bn | 18.77 Bn | 683.80 Mn | - |
| 10 | Inventiva | 693.72 Mn | 693.72 Mn | - | - |